Spacek M, Smolej L, Simkovic M, Nekvindova L, et al. Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR). Br J Haematol 2023 Mar 27. doi: 10.1111/bjh.18736.
PMID: 36971061